Resize text 
Resize text 
Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium is a collaborative European project that comprises a programme to address limitations of current methods in the field of pharmacoepidemiology and pharmacovigilance. The European Medicines Agency (EMA) is the coordinator of PROTECT and GSK is the deputy co-ordinator of PROTECT. They manage a multi-national consortium of 32 partners including academics, regulators, SMEs and EFPIA companies.
London, 7 May 2012 Today we have launched a two-week survey to gather feedback on the use of www.imi-protect.eu We are using the survey to gather information to help us plan the future development of the PROTECT website. It includes questions about who uses the website and why they use it. It is also collecting ideas for how the website could be improved. The survey is strictly to gather feedback on the public-facing website interface and not on password-protected applications that may relate to the website. The survey can be found at http://www.surveymonkey.com/s/H8P7DTL. It will take no more than five minutes to complete. It is open until Friday 18 May 2012. |
| Latest News | |
|---|---|
| 26-27 April 2012 | PROTECT Joint External Advisory Board & Steering Committee Meeting The 2012 Joint External Advisory Board & Steering Committee meeting will take place on 26-27 April at EMA. Each Work Package will have the opportunity to discuss their results, study protocols, and work plan with external experts who will provide advice and recommendations. See also: Governance structure |
| 26 March 2012 | PROTECT Conference A PROTECT Conference will take place on 22-23 October 2012 in Copenhagen and will be hosted by the Danish Health and Medicines Authority. The two-day meeting will consist in the PROTECT Consortium Assembly on the first day and Work Packages meetings on a second day. |
| 12 March 2012 | PROTECT - IMI Review The PROTECT co-leaders participated to a mid-term Expert review of the project organised by IMI in Brussels. The objectives of the meeting were to critically review the progress of the PROTECT project and make recommendations for. Generally, PROTECT was congratulated for the quality of the work, the progress of the project and the enthusiasm and commitment of its participants. The project is seen as a strong and long-standing support for developments in pharmacovigilance and pharmacoepidemiology.
|
